בריפלקס PN 250

Šalis: Izraelis

kalba: hebrajų

Šaltinis: Ministry of Health

Veiklioji medžiaga:

COAGULATION FACTOR II (HUMAN); COAGULATION FACTOR IX (HUMAN- RFIXFC); COAGULATION FACTOR VII (HUMAN); COAGULATION FACTOR X (HUMAN); PROTEIN C; PROTEIN S ANTIGEN

Prieinama:

CSL BEHRING LTD., ISRAEL

ATC kodas:

B02BD01

Vaisto forma:

אבקה וממס להכנת תמיסה להזרקה

Sudėtis:

COAGULATION FACTOR II (HUMAN) 200 - 480 IU; COAGULATION FACTOR VII (HUMAN) 100 - 250 IU; COAGULATION FACTOR IX (HUMAN- RFIXFC) 200 - 310 IU; COAGULATION FACTOR X (HUMAN) 220 - 600 IU; PROTEIN C 150 - 450 IU; PROTEIN S ANTIGEN 120 - 380 IU

Vartojimo būdas:

תוך-ורידי

Recepto tipas:

מרשם נדרש

Pagaminta:

CSL BEHRING GmbH, GERMANY

Farmakoterapinė grupė:

COAGULATION FACTOR IX, II, VII AND X IN COMBINATION

Gydymo sritis:

COAGULATION FACTOR IX, II, VII AND X IN COMBINATION

Terapinės indikacijos:

-Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.

Leidimo data:

2017-03-31